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Background: Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein
kinase, the activity of which is inhibited by a variety of extracellular stimuli
including insulin, growth factors, cell speci¢cation factors and cell adhesion.
Consequently, inhibition of GSK-3 activity has been proposed to play a role in the
regulation of numerous signalling pathways that elicit pleiotropic cellular
responses. This report describes the identi¢cation and characterisation of potent
and selective small molecule inhibitors of GSK-3.
Results: SB-216763 and SB-415286 are structurally distinct maleimides that
inhibit GSK-3K in vitro, with Kis of 9 nM and 31 nM respectively, in an ATP
competitive manner. These compounds inhibited GSK-3L with similar potency.
However, neither compound signi¢cantly inhibited any member of a panel of 24
other protein kinases. Furthermore, treatment of cells with either compound
stimulated responses characteristic of extracellular stimuli that are known to
inhibit GSK-3 activity. Thus, SB-216763 and SB-415286 stimulated glycogen
synthesis in human liver cells and induced expression of a L-catenin-LEF/TCF
regulated reporter gene in HEK293 cells. In both cases, compound treatment was
demonstrated to inhibit cellular GSK-3 activity as assessed by activation of
glycogen synthase, which is a direct target of this kinase.
Conclusions: SB-216763 and SB-415286 are novel, potent and selective cell
permeable inhibitors of GSK-3. Therefore, these compounds represent valuable
pharmacological tools with which the role of GSK-3 in cellular signalling can be
further elucidated. Furthermore, development of similar compounds may be of
use therapeutically in disease states associated with elevated GSK-3 activity such
as non-insulin dependent diabetes mellitus and neurodegenerative disease.
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Introduction
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine
protein kinase encoded by two highly homologous and
ubiquitously expressed genes. The catalytic domains of
mammalian GSK-3K and GSK-3L are 95% identical at
the amino acid level, whereas the amino- and carboxy-ter-
mini are less conserved [1]. GSK-3 was originally identi¢ed
by virtue of its ability to phosphorylate and inactivate gly-
cogen synthase, the rate limiting enzyme in glycogen syn-
thesis [2]. However, it is now apparent that GSK-3 has
many putative targets, including IRS-1 [3], the translation
initiation factor eIF2B [4], transcription factors c-jun [5],
CREB [6], NFAT [7], L-catenin [8], C/EBPK [9] and the
neuronal microtubule associated proteins MAP-1B [10,11]
and Tau [12^15] (Figure 1).
A variety of extracellular stimuli inhibit cellular GSK-3
activity, including insulin [16], growth factors [17^23],
Wnt cell speci¢cation proteins [24] and cell adhesion
[25]. Since these stimuli elicit a diverse range of responses
in a number of different cell types, inhibition of GSK-3
activity is potentially pivotal in mediating pleiotropic cel-
lular responses to external stimuli (Figure 1). However, the
potential role of GSK-3 inhibition in any given response is
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complicated by the fact that stimuli often initiate addition-
al signalling pathways to the one that affects GSK-3 activ-
ity. Therefore, in order to more de¢nitively implicate GSK-
3 inhibition in a response it is necessary to selectively
inhibit this kinase and assess whether this alone is suf¢-
cient to induce the response.
Antisense targeting of GSK-3 and the overexpression of a
dominant negative form of the kinase have both been used
to inhibit cellular GSK-3 activity [26,27]. However, these
techniques may have spurious effects on cell physiology
that are independent of GSK-3 inhibition. This is because
full or partial sequences targeted by antisense oligonucleo-
tides are predicted to be present in multiple mRNAs, not
just the one encoding the intended target (for review see
[28]). Sequestration of kinase activating factors or co-factors
by dominant negative kinases may also inhibit kinases in
addition to the target kinase. These genetic techniques
also have the disadvantage of being invasive, chronic inter-
ventions that again raise concerns about non-speci¢c ef-
fects on cell physiology.
LiCl is an ATP noncompetitive inhibitor of GSK-3L activ-
ity (Ki 2 mM) that has been used extensively in studies
investigating the functional role of GSK-3 [10,12,29^31]. It
has the advantage over genetic approaches of effecting an
acute inhibition of GSK-3 in cells. However, LiCl is not a
selective inhibitor of GSK-3 and has a number of addition-
al activities that complicate interpretation of data generated
from its use. Recently, LiCl has been reported as a low
mM inhibitor of casein kinase-2, p38 regulated/activated
kinase and MAPK activated protein kinase-2 [32]. Addi-
tionally, LiCl is a WM inhibitor of polyphosphate 1-phos-
phatase and inositol monophosphatase, two enzymes re-
quired for de novo synthesis of inositol and thus to
support phosphoinositide signalling (for review see [33]).
Paradoxically, LiCl has also been reported to acutely ele-
vate phosphatidylinositol 3-phosphate levels in rat cerebel-
lar granule cells, thereby activating PKB [34]. Activated
PKB phosphorylates and inhibits GSK-3, suggesting that
LiCl has the potential to inhibit this kinase both directly
and indirectly in cells.
Recent drug discovery programmes have demonstrated the
feasibility of identifying highly selective, cell permeable,
small molecule inhibitors of protein kinases (for reviews
see [35,36]). This report is the ¢rst to describe the directed
identi¢cation and characterisation of small molecule in-
hibitors of GSK-3. These compounds potently and selec-
tively inhibited GSK-3 in vitro. Furthermore, the com-
pounds elicited cellular responses that have been
previously attributed to inhibition of GSK-3. Therefore,
these compounds will be valuable pharmacological tools
with which to further elucidate the role of GSK-3 inhibi-
tion in mediating cellular responses to extracellular stimuli.
Moreover, these compounds and their derivatives may be
of therapeutic use in treating conditions associated with
elevated GSK-3 activity such as non-insulin dependent
Figure 1. Inhibition of GSK-3 activity
mediates pleiotropic cellular responses to
external stimuli. GSK-3 phosphorylates and
modulates the activity of a number of key
regulatory proteins (arrow in the ¢gure) in
the cell including: microtubule associated
proteins (Tau, MAP-1B); transcription
factors (L-catenin, NFAT); a translation
initiation factor (eIF2B) and glycogen
synthase. Consequently, external stimuli
that inhibit GSK-3 activity (hammerhead in
the ¢gure) have the potential to regulate a
broad range of cellular processes including
microtubule stability, gene transcription,
protein translation and glycogen
metabolism.
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diabetes mellitus [37,38] and neurodegenerative disease
[26,39].
Results
Identi¢cation of SB-216763 and SB-415286 as inhibitors of
GSK-3
Maleimide derivatives were identi¢ed as leads from a high
throughput screen of the SmithKline Beecham compound
bank against rabbit GSK-3K. The arylindolemaleimide SB-
216763 and anilinomaleimide SB-415286 [46] were subse-
quently identi¢ed as potent inhibitors of human GSK-3K
using a peptide-based protein kinase assay as described in
Materials and methods (structures in Figure 2). SB-216763
and SB-415286 inhibited human GSK-3K with IC50s of 34
nM and 78 nM respectively, when assayed in the presence
of 0.01 mM ATP (Figure 3A,B). These compounds inhib-
ited GSK-3K in an ATP competitive manner (Figure
4A,B). SB-216763 and SB-415286 inhibited GSK-3K with
Kis of 9 nM and 31 nM respectively (Figure 4A,B). SB-
216763 and SB-415286 were equally effective at inhibiting
human GSK-3K and GSK-3L (data not shown).
Selectivity of SB-216763 and SB-415286 as GSK-3
inhibitors
The selectivity of SB-216763 and SB-415286 was investi-
gated by testing the ability of these compounds to inhibit a
panel of 25 different serine/threonine and tyrosine protein
kinases. In the presence of 0.1 mM ATP, 10 WM SB-
216763 and SB-415286 inhibited GSK-3L kinase activity
by 96% and 83% respectively (Table 1). In contrast, these
compounds exhibited little or no inhibition of the other 24
members of the kinase selectivity panel.
SB-216763 and SB-415286 stimulate glycogen synthesis in
a human liver cell line
There is substantial evidence that insulin-induced inhibi-
tion of GSK-3 activity contributes to the ability of this
hormone to stimulate glycogen synthesis in muscle, liver
and fat cells [31,40^42]. Consistent with these reports, both
Figure 2. The chemical structures of SB-216763 and SB-415286.
(A) SB-216763 is 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-
1H-pyrrole-2,5-dione. (B) SB-415286 is 3-(3-chloro-4-
hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione.
Figure 3. SB-216763 and SB-415286 inhibit GSK-3 activity in
vitro. The ability of GSK-3K to phosphorylate a peptide substrate
was assessed in the presence of the indicated concentrations of
SB-216763 (A) or SB-415286 (B). Results are presented as the
percentage of GSK-3K activity in control incubations in which
compound was omitted. Data are mean þ S.E.M. from at least four
independent experiments, where each point was assayed in
quadruplicate.
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SB-216763 and SB-415286 stimulated glycogen synthesis
in the Chang human liver cell line with EC50s of 3.6 WM
and 2.9 WM respectively (Figure 5A). The maximum effec-
tive concentrations of SB-216763 and SB-415286 were 30
WM and 10 WM respectively. These concentrations of the
compounds stimulated glycogen synthesis to a greater de-
gree than a maximum stimulatory concentration of insulin
(Figure 5B). The non-selective GSK-3 inhibitor, LiCl, at
its maximum effective concentration (for LiCl dose re-
sponse see Figure 5C) stimulated glycogen synthesis sim-
ilarly to the compounds (Figure 5B). Maximum effective
concentrations of LiCl plus either SB-216763 or SB-415286
were not additive in their stimulation of glycogen synthesis
(Figure 5B). In contrast, insulin was additive with either
compound or LiCl in the stimulation of glycogen synthesis
(Figure 5B).
SB-216763 and SB-415286 activate glycogen synthase in
Chang human liver cells and in HEK293 cells
To determine whether the ability of SB-216763 and SB-
415286 to stimulate glycogen synthesis in liver cells re-
sulted from inhibition of GSK-3 activity in these cells,
the activity of glycogen synthase was assessed in com-
pound-treated cells. This enzyme represents a marker of
cellular GSK-3 activity as its activity is directly inhibited by
GSK-3 mediated phosphorylation. SB-216763, SB-415286,
Figure 4. SB-216763 and SB415286 inhibit GSK-3 activity in an
ATP competitive manner. The ability of SB-216763 (A) and SB-
415286 (B) to inhibit GSK-3K activity in the presence of the
indicated concentrations of ATP was studied. Control incubations
(S) and incubations carried out in the presence of SB-216763 or
SB-415286 at 30 nM (P), 60 nM (R), 100 nM (O), 200 nM (F),
300 nM (E), 400 nM (b) and 500 nM (a). Results are presented
as pmol of phosphate incorporated into peptide substrate/10 Wl of
sample/30 min. Data are means of duplicate assay wells.
Table 1
Effect of SB-216763 and SB-415286 on the activities of pro-
tein kinases in vitro.
Protein kinase Activity (% control)
SB-216763 SB-415286
AMPK 81 54
Chk1 90 75
CKII 95 82
GSK-3L 4 17
IRTK 84 81
JNK 99 101
Lck 101 81
MAPK 88 97
MAPKAPK-1L 96 38
MAPKAPK-2 94 96
MKK1 94 88
MSK1 95 81
p70 S6K 94 92
PDK1 100 92
Phos.K 117 100
PKA 102 93
PKBK 96 95
PKCK 77 70
PRAK 80 101
ROKK 92 109
SAPK2K 81 95
SAPK2L 95 106
SAPK3 104 111
SAPK4 82 92
SGK 98 97
Protein kinases were assayed þ 10 WM SB-216763 or SB-415286
in the presence of 0.1 mM ATP. Activities are given as the mean
of duplicate determinations relative to control incubations in which
the inhibitors were substituted with DMSO vehicle. Similar results
were obtained in a second independent screen of the same panel
of protein kinases. AMPK, AMP activated protein kinase; Chk,
checkpoint kinase; CKII, casein kinase-2; GSK-3, glycogen syn-
thase kinase-3; IRTK, insulin receptor tyrosine kinase; JNK, c-Jun
N-terminal kinase; Lck, lymphocyte c-src kinase; MAPK, mitogen
activated protein kinase; MAPKAPK, MAPK activated protein ki-
nase; MKK, MAPK kinase; MSK1, mitogen and stress activated
protein kinase-1; p70 S6K, p70 ribosomal protein S6 kinase;
PDK1, 3-phosphoinositide dependent protein kinase-1; Phos.K,
phosphorylase kinase; PKA, protein kinase A; PKB, protein kinase
B; PKC, protein kinase C; PRAK, p38 regulated/activated kinase;
ROK, Rho dependent protein kinase; SAPK, stress activated pro-
tein kinase; SGK, serum and glucocorticoid induced kinase.
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LiCl and insulin each stimulated glycogen synthase activ-
ity in Chang human liver cells (Figure 6A). The com-
pounds and LiCl each activated glycogen synthase to a
greater degree than insulin. Treatment of cells with either
compound plus LiCl did not elicit an additive activation of
glycogen synthase. However, the activation of glycogen
synthase by insulin was additive to that effected by com-
pounds or LiCl (Figure 6A). SB-216763, SB-415286 and
LiCl were also each capable of inhibiting GSK-3 activity
in the HEK293 human embryonic kidney cell line as dem-
onstrated by their ability to activate glycogen synthase in
these cells (Figure 6B).
SB-216763 and SB-415286 induce transcription of a L-
catenin-LEF/TCF regulated reporter gene in HEK293 cells
GSK-3 phosphorylation of L-catenin targets this protein for
ubiquitin mediated proteasomal degradation [8]. Conse-
quently, in quiescent cells in which GSK-3 activity is
high, cytosolic and nuclear levels of L-catenin remain
low. Inhibition of GSK-3 activity by the cell speci¢cation
factor Wnt [24] promotes the stabilisation and accumula-
tion of cytosolic L-catenin. Accumulated cytosolic L-catenin
binds to members of the lymphoid enhancer factor/T cell
factor (LEF/TCF) transcription factor family. The result-
ing complex is shuttled to the nucleus where it regulates
Figure 5. SB-216763 and SB-415286 stimulate glycogen synthesis in Chang human liver cells. Chang cells were incubated in serum-free
medium for 16 h. Serum starved Chang cells were treated for 60 min with the indicated concentration of (A) SB-216763 (a) or SB-415286
(b), (B) 30 WM SB-216763, 10 WM SB-415286, 10 mM LiCl or 1 WM insulin and (C) 2, 10 and 50 mM LiCl (¢lled bars) or NaCl (open
bars). Cells not exposed to compound were exposed to DMSO vehicle. After 60 min of treatment, [14C]glucose was added and the cells
were incubated for a further 75 min. Cells were then extracted into 20% (w/v) KOH and total cell glycogen was isolated by ethanol
precipitation. Glycogen pellets were resuspended in H2O and [14C]glucose incorporation was assessed by scintillation counting. Results are
expressed as fold stimulation of glycogen synthesis observed in control cells treated with DMSO vehicle. Data are mean þ S.E.M. for four
independent experiments where each point represents quadruplicate cell treatments. *P60.05, ***P6 0.001 vs insulin alone and
8P6 0.05, 88P6 0.01 and 888P60.001 vs LiCl or compound alone.
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gene expression [24,43]. Using a HEK293 transient trans-
fection L-catenin-LEF/TCF luciferase reporter assay, SB-
216763 and SB-415286 were observed to dose-dependently
induce transcription of the L-catenin dependent gene (Fig-
ure 7A,B). The maximum effective concentrations of SB-
216763 and SB-415286 in this assay were 5 WM and 30 WM
respectively. Neither compound induced the expression of
a control reporter gene which is insensitive to L-catenin
owing to mutation of the LEF/TCF binding sites (Figure
7A,B). Similar to the compounds, LiCl induced a dose
dependent activation of the reporter gene (Figure 7C).
In contrast to SB-216763 and SB-415286, LiCl also stimu-
lated induction of the control, L-catenin independent re-
porter (Figure 7C). NaCl had no effect on transcription of
either reporter gene (Figure 7D).
Discussion
This report describes the identi¢cation of the arylindole-
maleimide SB-216763 and the anilinomaleimide SB-
415286 as potent inhibitors of GSK-3. In common with
most other protein kinase inhibitors these compounds in-
hibit their target protein kinase in an ATP competitive
manner [35,36]. Therefore, these compounds inhibit
GSK-3 in vitro at 0.01 mM ATP with IC50s less than 100
nM but approximately 100-fold higher concentrations are
required in order to observe compound effects in cells
where ATP is present at 1^2 mM [35].
The utility of protein kinase inhibitors as research tools or
potential therapeutic agents is dependent upon their abil-
ity to selectively inhibit the target protein kinase. SB-
216763 and SB-415286 are highly selective inhibitors of
GSK-3. Therefore, under conditions in which SB-216763
and SB-415286 completely abolished GSK-3 activity, these
two compounds did not affect the activity of 24 different
serine/threonine and tyrosine protein kinases that were
tested. Moreover, the ¢nding that neither SB-216763 nor
SB-415286 inhibited the activity of those kinases required
for insulin signalling and cell survival (IRTK, p70 S6K,
PDK1, phosphorylase kinase, PKB) suggests that these
compounds may be of use therapeutically in disease states
associated with elevated GSK-3 activity such as diabetes
and neurodegenerative disorders.
The value of these compounds as tool GSK-3 inhibitors
was evidenced by their ability to induce cellular responses
that had previously been attributed to inhibition of GSK-3
activity. SB-216763 and SB-415286 both stimulated glyco-
gen synthesis in human liver cells and this effect was ad-
ditive with the stimulation elicited by insulin. This sug-
gests that in these cells, insulin and GSK-3 inhibitors effect
their responses through distinct molecular pathways (Fig-
ure 8). It is likely that in this case insulin acts through
stimulating the MAPK/MAPKAPK-1L/PP1G pathway,
rather than through inhibition of GSK-3, to stimulate gly-
cogen synthase and hence glycogen synthesis [40,44].
The non-selective GSK-3 inhibitor, LiCl, also stimulated
glycogen synthesis in these cells and this effect was
also additive with that of insulin. However, co-treatment
of cells with either SB-216763 or SB-415286 in combina-
Figure 6. SB-216763 and SB-415286 activate glycogen synthase
in Chang human liver cells and HEK293 cells. Serum starved
Chang cells were treated for 60 min with (A) 30 WM SB-216763,
10 WM SB-415286, 10 mM LiCl or 1 WM insulin. Serum starved
HEK293 cells (B) were treated for 90 min with 5 WM SB-216763,
40 WM SB-415286 or 20 mM LiCl. Cells not exposed to
compound were exposed to DMSO vehicle. Cells were harvested
and cell lysates were prepared. Lysate supernatants were
assayed for glycogen synthase activity þ glucose 6-phosphate.
Results are expressed as fold stimulation of the glycogen
synthase activity ratio observed in control cells treated with
DMSO vehicle. Data are mean þ S.E.M. for three independent
experiments where each point represents duplicate cell
treatments. *P6 0.05, **P6 0.01 vs insulin alone and 8P6 0.05,
88P6 0.01 vs LiCl or compound alone.
CHBIOL 24 2-10-00 Cyaan Magenta Geel Zwart
798 Chemistry & Biology 2000, Vol 7 No 10
tion with LiCl did not produce an additive stimulation of
glycogen synthesis. This is consistent with the effects of
the compounds being mediated by inhibition of GSK-3
activity.
The best established functional consequence of GSK-3
inhibition is the activation of glycogen synthase, the rate
limiting enzyme in glycogen synthesis. As expected, from
their ability to induce glycogen synthesis, SB-216763 and
SB-415286 each activated glycogen synthase in human liv-
er cells. Furthermore, the additivity or otherwise of com-
pound effects with those of insulin or LiCl at the level of
glycogen synthase paralleled those effects observed at the
level of glycogen synthesis. Thus, compound or LiCl plus
insulin exhibited an additive activation of glycogen syn-
thase whereas compound plus LiCl did not. The additive
stimulation of glycogen synthase and glycogen synthesis by
maximum effective concentrations of LiCl plus insulin has
been reported previously in liver and fat cells [31,45].
Further evidence for the utility of SB-216763 and SB-
415286 as tool GSK-3 inhibitors was provided by the abil-
ity of these compounds to induce expression of a L-catenin
regulated reporter gene in HEK293 cells. In this assay, SB-
216763 produced a maximum 2.5-fold induction of the
reporter gene at 5 WM whereas SB-415286 produced a
Figure 7. SB-216763 and SB-415286 induce transcription of a L-catenin-LEF/TCF regulated reporter gene. HEK293 cells were transiently
transfected with L-catenin-LEF/TCF sensitive (b) or L-catenin-LEF/TCF insensitive (a) luciferase reporter genes. Serum starved cells were
then treated for 16 h with the indicated concentration of SB-216763 (A), SB-415286 (B), LiCl (C) or NaCl (D). Cell extracts were prepared
and assayed for luciferase activity. Results are expressed as fold induction of reporter gene expression over that observed in control cells
treated with DMSO vehicle (A,B) or serum-free medium alone (C,D). Data are mean þ S.E.M. for four independent experiments where each
point represents triplicate cell treatments.
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maximum 5-fold induction at 30 WM. It seems unlikely
that the lower effect of SB-216763 compared to SB-
415286 results from its poorer cell penetration in 293 cells
as both compounds induced a similar activation of glycogen
synthase in these cells. However, the cells were only ex-
posed to compounds for 90 min prior to preparation of cell
extracts for glycogen synthase assay, whereas the reporter
assay involved compound treatment of cells for 16 h. This
is important as SB-216763 was observed to precipitate out
of solution in a time dependent manner. SB-216763 con-
taining medium that had been incubated for 16 h, under
conditions identical to those used in the reporter assay, was
microscopically examined. At concentrations above 5 WM,
SB-216763 was clearly observed to precipitate out of solu-
tion in this culture medium (unpublished observations).
No such precipitation of SB-216763 was apparent after
shorter incubation of this compound under conditions
identical to those used in glycogen synthase or glycogen
synthesis assays. Therefore, the reduced ability of SB-
216763 compared with SB-415286, to induce L-catenin
regulated reporter gene transcription can be attributed to
the low solubility of this compound upon prolonged incu-
bation in aqueous media.
The observation that LiCl dose dependently induced the
expression of a L-catenin insensitive, control reporter gene
highlights the concerns associated with the use of this non-
selective agent as a tool GSK-3 inhibitor. However, the use
of LiCl in combination with SB-216763 or SB-415286 can
be used to implicate GSK-3 inhibition in a given response
as demonstrated by their non-additivity in stimulating gly-
cogen synthesis/glycogen synthase in liver cells.
Signi¢cance
Elucidation of the functional consequences of inhibiting
GSK-3 activity in a given cell type requires a means by
which the activity of this kinase can be selectively inhib-
ited. Genetic approaches to reducing cellular GSK-3 activ-
ity such as the use of antisense oligonucleotides or the
overexpression of dominant negative GSK-3 are chronic,
invasive and labour intensive techniques that are likely
to have additional non-speci¢c effects on cell physiology.
Whilst LiCl is capable of acutely inhibiting cellular GSK-3
activity, it also inhibits a number of other protein kinase
and non-kinase targets. This report describes the identi¢-
cation of the arylindolemaleimide SB-216763 and the ani-
linomaleimide SB-415286, as highly selective, potent and
cell permeable inhibitors of GSK-3. These compounds
acutely reduce cellular GSK-3 activity as assessed by acti-
vation of glycogen synthase. Consistent with this, SB-
216763 and SB-415286 are each capable of eliciting re-
sponses that had been previously attributed as resulting
from the inhibition of GSK-3 activity. Therefore, SB-
216763 and SB-415286 represent valuable pharmacological
tool compounds that will be of use in further elucidating
the role of GSK-3 in cell signalling pathways. Furthermore,
development of similar compounds may be of use thera-
peutically in disease states associated with elevated GSK-3
activity such as non-insulin dependent diabetes mellitus
and neurodegenerative disease.
Figure 8. Proposed mechanism by which
small molecule GSK-3 inhibitors in
combination with insulin induce an additive
stimulation of glycogen synthase/synthesis
in Chang liver cells. Insulin can stimulate
glycogen synthase/synthesis through both
GSK-3 dependent and GSK-3 independent
pathways. The latter pathway involves the
activation of a protein serine/threonine
phosphatase (PP1G glycogen targeted
protein phosphatase-1) that
dephosphorylates and activates glycogen
synthase. The relative role of these two
pathways in mediating insulin's stimulation
of glycogen synthase/synthesis is cell type
dependent (see [40^42,44]). The additive
stimulation of glycogen synthase/synthesis
in Chang cells elicited by SB-216763, SB-
415286 or LiCl in combination with insulin
suggests that in this cell line insulin exerts
its effects through the activation of PP1G
rather than through the inhibition of GSK-3.
Hammerheads and arrows denote
inhibition and activation respectively. Solid
lines represent direct effects. Broken lines
indicate a multi-component pathway.
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Materials and methods
Materials
SB-216763 and SB-415286 were synthesised according to procedures
previously described [46,47]. 100 mM stock solutions of compounds
were prepared in dimethylsulphoxide (DMSO) and the ¢nal DMSO con-
centration in cellular assays was 0.1% (v/v). Cell culture reagents were
purchased from Life Technologies. Cell lines were from the American
Type Culture Collection. Radioisotopes were purchased from Amersham
Pharmacia. Human insulin was ActRapid from Novo Nordisk. Unless
otherwise indicated all other reagents were purchased from Sigma
Chemical Company.
Cell culture
Chang human liver cells were cultured in minimal essential medium
supplemented with 10% (v/v) foetal calf serum (FCS) and 1% (v/v)
non-essential amino acids. E1A-transformed human embryonic kidney
293 (HEK293) cells were maintained in Dulbecco's modi¢ed Eagle's
medium supplemented with 10% (v/v) heat inactivated FCS and 2 mM
glutamine. Chang cells were grown to con£uence and serum starved for
16 h prior to experimental use. Incubation of cells with compounds, LiCl
or insulin was performed at 37³C, 5% (v/v) CO2.
Expression and puri¢cation of recombinant human GSK-3K
Full length GSK-3K was ampli¢ed by polymerase chain reaction from a
human adult liver cDNA library. Following sequence con¢rmation, the
GSK-3K clone was subcloned into a baculovirus transfer vector contain-
ing a HexaHis tag. Recombinant baculovirus encoding GSK-3K was
produced and used to infect Sf9 insect cells. GSK-3K was puri¢ed
from lysates prepared from these cells using a four step strategy as
follows: NiNTA (Qiagen) chromatography (elution with 20 mM imidazole
followed by 300 mM imidazole); Source15S (Amersham Pharmacia)
cation exchange chromatography (NaCl gradient elution); NiNTA chro-
matography (20^300 mM imidazole gradient elution) and Source15S
cation exchange chromatography (NaCl gradient elution). The peak frac-
tions from the ¢nal stage were 94% pure by reverse phase HPLC. The
protein was stored in a 50% glycerol buffer at 380³C and retained
activity for greater than 6 months.
GSK-3 activity assay
GSK-3 kinase activity was measured, in the presence or absence of SB-
216763 or SB-415286, in a reaction mixture containing ¢nal concentra-
tions of: 1 nM human GSK-3K or rabbit GSK3K (Upstate Biotechnology
Inc.); 50 mM MOPS pH 7.0; 0.2 mM EDTA; 10 mM Mg-acetate; 7.5 mM
L-mercaptoethanol; 5% (w/v) glycerol; 0.01% (w/v) Tween-20; 10% (v/v)
DMSO; 28 WM GS-2 peptide substrate (Upstate Biotechnology Inc.). The
GS-2 peptide sequence corresponds to a region of glycogen synthase
that is phosphorylated by GSK-3 as previously described [18]. The as-
say was initiated by the addition of 0.34 WCi [33P]Q-ATP (IC50 determi-
nations) or 2.7 WCi [33P]Q-ATP (Ki determinations). The total ATP con-
centration was 10 WM (IC50 determinations) or ranged from 0 to 45 WM
(Ki determinations). Following 30 min incubation at room temperature
the assay was stopped by the addition of one third assay volume of
2.5% (v/v) H3PO4 containing 21 mM ATP. Samples were spotted onto
P30 phosphocellulose mats and these were washed six times in 0.5%
(v/v) H3PO4. The ¢lter mats were sealed into sample bags containing
Wallac betaplate scintillation £uid. 33P incorporation into the substrate
peptide was determined by counting the mats in a Wallac microbeta
scintillation counter.
Selectivity panel protein kinase assays
Human insulin receptor was partially puri¢ed from a cell line overex-
pressing this gene as described previously [48]. Insulin receptor tyrosine
kinase was activated by pre-incubation with 100 nM insulin. Compound
effects on insulin receptor tyrosine kinase activity and that of the other
members of the kinase selectivity panel were assessed as described
previously [32]. Brie£y, activated protein kinases were assayed for their
ability to phosphorylate the appropriate peptide/protein substrate in the
presence of 10 WM SB-216763 or SB-415286 at 0.1 mM ATP. All protein
kinase activities were linear with respect to time over the course of the
assay incubations.
Glycogen synthesis assay
Chang cells in 48 well plates were pre-incubated with insulin, compound
or DMSO vehicle. After 60 min, 2 WCi [14C]glucose was added to each
well and the plates incubated for a further 75 min. Wells were then
aspirated and washed with 1U400 Wl phosphate buffered saline (PBS)
before cell extraction into 150 Wl 20% (w/v) KOH for 1 h at 37³C. 90 Wl of
1 mg/ml carrier glycogen was added to each well. Following the addition
of 540 Wl absolute ethanol, total glycogen was precipitated overnight at
320³C. Glycogen precipitates were recovered by centrifugation at
1100Ug for 20 min at room temperature. Precipitates were resus-
pended in 75 Wl hot tap water and transferred to Packard 96 well Opti-
Plates. 150 Wl of Microscint-40 (Packard) was added to each well and
[14C]glucose incorporation into glycogen was assessed using a Packard
TopCount scintillation counter.
Glycogen synthase assay
Cells on 10 cm diameter dishes were treated with compound, DMSO
vehicle, LiCl or insulin for 60 (Chang cells) or 90 min (HEK293 cells).
Incubation medium was removed and cells washed with 1U5 ml ice-
cold PBS prior to lysis, on ice, in 450 Wl 20 mM Tris^HCl pH 7.4, 50 mM
NaF, 5 mM Na4P2O7, 2 mM Na3VO4, 10 mM L-glycerophosphate, 1 mM
EDTA, 1 mM EGTA, 0.1% (v/v) L-mercaptoethanol, 1% (w/v) Triton X-
100. Cell lysates were centrifuged at 15 000Ug for 5 min at 4³C. Lysate
supernatants were snap frozen on liquid nitrogen and stored at 380³C
prior to assay. Lysates were assayed for glycogen synthase activity in
buffer (67 mM Tris^HCl pH 7.5, 5 mM DTT, 6.7 mM EDTA, 13 mg/ml
glycogen, 8.9 mM [14C]UDP-glucose) in the presence or absence of
20 mM glucose 6-phosphate as described previously [41]. Data are
expressed as fold increases in glycogen synthase activity ratios over
those of control. Activity ratios of glycogen synthase in control cells
were approximately 0.15 and 0.05 in Chang and HEK293 cells respec-
tively.
L-Catenin-LEF/TCF regulated reporter gene assay
Two 10 cm diameter dishes were seeded with 3U106 HEK293 cells.
The following day, the cells were transfected with 4 Wg of either a L-
catenin-LEF/TCF sensitive or a L-catenin-LEF/TCF insensitive reporter
vector (Upstate Biotechnology Inc.) using Lipofectamine Plus reagent
(GibcoBRL) according to the manufacturer's instructions. The next
day, cells were trypsinised, washed into serum-free medium, counted
and seeded at 40 000 cells per well in a 96 well plate. Subsequent to
cell attachment, LiCl or GSK-3 inhibitor compounds were added to the
medium to the required concentrations. Control cells were DMSO ve-
hicle treated. 16 h after inhibitor addition, cells were analysed for lucif-
erase activity using the Steady-Glo Luciferase assay system (Promega)
according to the manufacturer's instructions.
Statistical analysis
Results are presented as meanþ S.E.M. unless stated. Statistical anal-
ysis was performed by a Dunnett test for unpaired data using Statistica
for Windows (Release 5.1, 1997 edition).
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